regorafenib
Selected indexed studies
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. (Lancet, 2013) [PMID:23177514]
- Regorafenib. (Recent Results Cancer Res, 2018) [PMID:30069758]
- Regorafenib for the Treatment of Sarcoma. (Curr Treat Options Oncol, 2022) [PMID:36178573]
_Worker-drafted node — pending editorial review._
Connections
regorafenib is a side effect of
Sources
- Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. (2019) pubmed
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. (2013) pubmed
- Regorafenib. (2018) pubmed
- Regorafenib for the Treatment of Sarcoma. (2022) pubmed
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. (2017) pubmed
- Regorafenib inhibits EphA2 phosphorylation and leads to liver damage via the ERK/MDM2/p53 axis. (2023) pubmed
- Regorafenib. (2014) pubmed
- Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. (2015) pubmed
- Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study. (2023) pubmed
- Regorafenib: A Review in Hepatocellular Carcinoma. (2018) pubmed